Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Progenity, Inc. (PROG)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
3.6400-0.1100 (-2.93%)
At close: 1:00PM EST
3.5600 -0.08 (-2.20%)
After hours: 04:59PM EST
Advertisement
Sign in to post a message.
  • A
    Abby
    I believe short interest is down because many shorts have covered their positions via darkpool abuse and during that run up from 2.97 to 6.20. The reason I think many coveted is because within a few weeks PROG will likely release some crazy news of partnerships, which will cause this thing to go ballistic. Shorts have either been warned about this behind closed doors, or they have some insider information, hence they’ve covered. Subsequently PROG set themselves up perfectly with the ATM offering because they know after the PR is released and this goes 🚀 mode, they want to capitalize off that and make an additional 90 million for the company. It all adds up, shorts are being proactive before they get stuck in this for good at much higher price points. Now that short interest is possibly down to about 9%, means most shorts are out, hence PROG is likely ready to release their PR within a few weeks. 30+ incoming
    Bullish
  • j
    joseph
    iam long 20k shares and continue to believe in this company based on the fundementals ............not on the b/s the youtubers are saying about short squeezes ........they make money producing videos and are not held to be honest.......just guessing about shorts
    Bullish
  • T
    Tucker
    Wow! Michael has posted 9 times in the last hour! Seems pretty desperate to me. 😂😂😂
    Bullish
  • J
    Johnny2Thumbs
    People here are acting like the sky is falling because they're not seeing 50% or more returns on this stock in a day. Just the other week it dropped a $1 a share and bounced back. It'll do it again and again and each time the level of support is raised. Nothing has changed fundamentally with PROG. It's still a great opportunity. The overall market has been down and this is a holiday week with low volume. It's all very typical for this time of year.
  • A
    Abby
    Glad this week is done. Certainly seems like we’ve found a bottom at 3.40-3.60, solid support all week tested it 3 times. And gap of 3.47 officially filled today which is a great takeaway from the week. Only way is up from here. New week, new trend, green all week coming up.
  • U
    Uncle
    We get any catalyst and this will pass $12 easy. May take 2 days. But this is not a one trick pony.
    Bullish
  • A
    Abby
    This’ll bounce right back, next week, we’ll trade in the 4.50-5.50 range until we get some sort of solid PR which will then push us to 7.50+. Next week we bounce back to high 4’s/low 5’s and consolidate there until we get our PR.
    Bullish
  • E
    Erira
    Michael just leave
    Bullish
  • J
    JJK3
    Love to see this get past 5.50 sometime soon
  • M
    Mr. Murdock
    BOOM!!!! Let the squeeze commence! Big news! Ionis gets thumbs up from Pfizer on Antisense vupanorsen for top results clinical 2B. Which just so happens to be the same thing Ionis and $Prog inked agreement on back in April or May. Agreement to make OBDS for antisense oligonucleotide! Load UP just came out today!

    On the clinical front, Ionis inked an agreement with San Diego-based Progenity to study the safety, tolerability and performance of Progenity’s Oral Biotherapeutics Delivery System (OBDS) for oral dosing of Ionis’ antisense oligonucleotides. Ionis’ antisense drugs work by targeting mRNA, so the amount of disease-causing protein is decreased; they can also treat diseases caused by too little protein by increasing protein production.

    OBDS is an ingestible capsule based on Progenity’s needle-free technology. It allows a drug to be formulated in a way that it can be delivered directly into the tissues of the small intestine, where it will be systemically absorbed.

    “We’re excited to work with Ionis, a leader in nucleic-acid-based biotherapeutics, to collectively evaluate the ODBS platform for the oral delivery of antisense therapies,” said Harry Stylli, chief executive officer, chairman and co-founder of Progenity. “We believe the OBDS platform shows promise to transform the systemic delivery of diverse biotherapeutics via oral administration.”
    Bullish
  • J
    JAMES
    $Prog Ionis gets thumbs up from Pfizer on Antisense vupanorsen for top results clinical 2B. Which just so happens to be the same thing Ionis and $Prog inked agreement on back in April or May. Agreement to make OBDS for antisense oligonucleotide! Load UP just came out today!
  • N
    Nick
    This thing is going to fly
    Bullish
  • K
    Kermit
    Nice hold today.
  • J
    Josh
    Wheres the squeeze?
  • G
    Gerard
    Tomorrow over 4 usd to prepare huge Xmas Rally! Happy Thanksgiving Everybody!
    Bullish
  • J
    Johnny2Thumbs
    The fact that we have strong support in the $3.60 - $3.70 range is a great sign. I fully expect it to bounce upwards next week.
  • A
    A
    Michael.
  • J
    JAMES
    Big Things are Happening
    Just Wait
  • J
    JAMES
    Michael Cleary isn't Wired right
    Don't respond to him
    The Guys Not Well
  • M
    Michael
    Pfizer just announced they are happy with results of a drug that Ionis (with an i at beginning) ticker symbol IONS in phase 2B is making in partnership with Progenity to orally deliver the therapeutic. Pfizer says they are considering next steps. https://twitter.com/kiwonah/status/1463864006385577984?s=10. Check it out
    Bullish
Advertisement
Advertisement